共 50 条
- [41] Efficacy of Letrozole as First-Line Treatment of Postmenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer in KoreaCANCER RESEARCH AND TREATMENT, 2017, 49 (02): : 454 - 463Beom, Seung HoonOh, JisuKim, Tae-YongLee, Kyung-HunYang, YaewonSuh, Koung JinMoon, Hyeong-GonHan, Sae-WonOh, Do-YounHan, WonshikKim, Tae-YouNoh, Dong-YoungIm, Seock-Ah
- [42] First-line endocrine therapy for postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and meta-analysisBreast Cancer, 2020, 27 : 340 - 346Tatsunori ShimoiYasuaki SagaraFumikata HaraTatsuya ToyamaHiroji Iwata
- [43] First-line vs second-line fulvestrant for hormone receptor-positive advanced breast cancer: A post-hoc analysis of the CONFIRM studyBREAST, 2018, 38 : 144 - 149Di Leo, AngeloJerusalem, GuyTorres, RobertoVerhoeven, DidierPendergrass, KellyMalorni, LucaLichfield, JasmineMartin, Miguel
- [44] First-line Treatment with Ribociclib plus Endocrine Therapy for Premenopausal Women with Hormone-receptor-positive Advanced Breast Cancer: A Cost-effectiveness AnalysisCLINICAL BREAST CANCER, 2021, 21 (04) : E479 - E488Huang, XiaotingLin, ShenRao, XinZeng, DayongWang, HangWeng, XiuhuaHuang, Pinfang
- [45] Fulvestrant: Expanding the endocrine treatment options for patients with hormone receptor-positive advanced breast cancerBREAST, 2008, 17 : S16 - S21Chia, StephenGradishar, William
- [46] Trastuzumab, leuprorelin, letrozole, and palbociclib as first-line therapy in HER2-positive and hormone receptor-positive metastatic breast cancer: A case reportMEDICINE, 2023, 102 (24) : E33975Sun, MaobenCai, LiangzhenChen, Min
- [47] Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance)JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (22) : 2602 - U86Dickler, Maura N.Barry, William T.Cirrincione, Constance T.Ellis, Matthew J.Moynahan, Mary EllenInnocenti, FedericoHurria, ArtiRugo, Hope S.Lake, Diana E.Hahn, OlwenSchneider, Bryan P.Tripathy, DebasishCarey, Lisa A.Winer, Eric P.Hudis, Clifford A.
- [48] Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: a review of subgroup analyses from the MONALEESA-2 trialBreast Cancer Research, 20Gabriel N. Hortobagyi
- [49] A European, Observational Study of Endocrine Therapy Administration in Patients With an Initial Diagnosis of Hormone Receptor-Positive Advanced Breast CancerCLINICAL BREAST CANCER, 2018, 18 (04) : E613 - E619Bastiaannet, EstherCharman, JackieJohannesen, Tom BorgeSchrodi, SimoneSiesling, Sabinevan Eycken, LiesbetWalsh, Paul M.Audisio, Riccardo A.Boelens, Petra G.Rubio, Isabel T.Jones, NickLewis, Janvan de Velde, Cornelis J. H.
- [50] Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: A Nation-Wide Multicenter Epidemiological Study in ChinaFRONTIERS IN ONCOLOGY, 2021, 10Wu, YunHan, YiqunYu, PeiOuyang, QuchangYan, MinWang, XiaojiaHu, XichunJiang, ZefeiHuang, TaoTong, ZhongshengWang, ShusenYin, YongmeiLi, HuiYang, RunxiangYang, HuaweiTeng, YueeSun, TaoCai, LiLi, HongyuanChen, XiHe, JianjunLiu, XinlanYang, ShuneQiao, YoulinFan, JinhuWang, JiayuXu, Binghe